Decreased glycolytic enzyme activity in epiphyseal cartilage of cortisone-treated rats

Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents

Osteoarthritis (OA) is the most common cause of disability worldwide among the elderly. Alarmingly, the incidence of OA in individuals less than 40 years of age is rising, likely due to the increase in obesity and post-traumatic osteoarthritis (PTOA). In recent years, due to a better understanding of the underlying pathophysiology of OA, several potential therapeutic approaches targeting specific molecular pathways have been identified. In particular, the role of inflammation and the immune system has been increasingly recognized as important in a variety of musculoskeletal diseases, including OA. Similarly, higher levels of host cellular senescence, characterized by cessation of cell division and the secretion of a senescence-associated secretory phenotype (SASP) within the local tissue microenvironments, have also been linked to OA and its progression. New advances in the field, including stem cell therapies and senolytics, are emerging with the goal of slowing disease progression. Mesenchymal stem/stromal cells (MSCs) are a subset of multipotent adult stem cells that have demonstrated the potential to modulate unchecked inflammation, reverse fibrosis, attenuate pain, and potentially treat patients with OA. Numerous studies have demonstrated the potential of MSC extracellular vesicles (EVs) as cell-free treatments that comply with FDA regulations. EVs, including exosomes and microvesicles, are released by numerous cell types and are increasingly recognized as playing a critical role in cell-cell communication in age-related diseases, including OA. Treatment strategies for OA are being developed that target senescent cells and the paracrine and autocrine secretions of SASP. This article highlights the encouraging potential for MSC or MSC-derived products alone or in combination with senolytics to control patient symptoms and potentially mitigate the progression of OA. We will also explore the application of genomic principles to the study of OA and the potential for the discovery of OA phenotypes that can motivate more precise patient-driven treatments.

Corticosteroid injection into the osteoarthritic knee: drug selection, dose, and injection frequency

OBJECTIVE

Although some disagreement exists amongst practitioners as to the efficacy of corticosteroid injection into the osteoarthritic knee, this procedure remains the most common reason to perform knee joint injection. There is disagreement too over the most efficacious corticosteroid for the procedure; the dose required at injection; the frequency, and total quantity of corticosteroid that can be injected into the knee. This paper examines the controversies surrounding the efficacy of corticosteroid injection into the osteoarthritic knee, and attempts to provide guidance as to appropriate corticosteroid selection, dose, and treatment interval.

METHOD

Searches were made of electronic databases, and appropriate papers were identified and hand-searched.

RESULTS AND CONCLUSION

Although numerous investigations have been conducted in an attempt to identify the optimal corticosteroid agent, and its optimal dosing regimen for the intra-articular treatment of osteoarthritis, a consensus has not been established. The current recommendations for dosing interval appear to have arisen as a consequence of a misinterpretation of previously published works. This paper recommends that practitioners refine and individually tailor their selection of agent and dosing regimen to patient needs and clinical response.

Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interim long-term analysis

The low interference with growth expected in child for a cortisol analogue, deflazacort (DFZ), prompted us to verify if DFZ could affect growth less than prednisone (PDN). An interim analysis relative to 27 girls and 38 boys (out of 100 expected) aged 3-12 yrs, after a median period of 14 mo.s is reported. Children with connective tissues (CTD) and glomerular disorders (KD) were randomly allocated to DFZ or PDN. Anthropometric measurements and maturity ratings were performed. Mean daily doses of PDN (or DFZ equivalent), from 0.57 to 0.64 mg/kg (DFZ 0.92 to 0.94 mg/kg) to induce control and from 0.19 to 0.39 mg/kg (DFZ 0.34 to 0.36 mg/kg) to maintain disease under control were given in CTD and KD, respectively. The increase in bone age delay over time was significantly greater than for PDN (-4.0 mo/yr) than DFZ (-1.8 mo/yr) in the overall group. The increases in statural age delay and loss over time were significantly greater than for PDN (-5.9 and -5.9 mo/yr) than DFZ (-2.4 and -2.4 mo/yr), only in children with "taller" midparents. Although doses of DFZ 1.1-1.8 times those of PDN were given, growth retardation in PDN-treated children was nevertheless 2.3-2.5 times that in DFZ-ones.

Transplacental effects of cortisone acetate on calcification and ossification of long bones in mice

The transplacental effects of cortisone acetate on the skeleton of neonatal mice has been investigated. Pregnant mice were injected intramuscularly with 0.75 mg cortisone acetate daily on days 11-19 of gestation. The mice were allowed to deliver and pups were weighed on days 1, 3, 5, 10, 15, 20 and 30 and compared to controls. Light microscopy of non-decalcified longitudinal sections of bones revealed mineral precipitates throughout the zone of hypertrophic cartilage most prominent on days 1, 3 and 5 and gradually disappearing on days 10-20. Transmission electron microscopy revealed intracellular calcification of maturing and hypertrophic chondrocytes in addition to abnormal calcification of the interstitial substance. Hydroxylapatite crystals were not necessarily associated with matrix vesicles. Scanning electron microscopy of long bones revealed a wide zone of calcified intercartilagenous matrix representing the calcified proliferating and hypertrophic zones. In this area, the calcospherites varied in size (0.5-1.4 mu in diameter) and were found in both longitudinal and transverse septa. No significant differences in the distribution and shape of cartilage matrix vesicles between experimental and control animals was observed. However, the fact that mineral crystals in experimental animals was not necessarily associated with matrix vesicles points to the possibility that this "pathological calcification" may utilize a different mechanism than the normal process through matrix vesicles.

Corticosteroid-induced changes in glucose metabolism of chondrocytes

Immature mice were treated for up to 12 weeks with daily doses of triamcinolone diacetate. Using quantitative histochemical methods, the proximal epiphyseal plate of the humerus was studied at regular intervals. By the tenth injection significant decrease was noted in the acid glycosaminoglycans content (25%) and in the neutral mucopolysaccharides (30%). Concomitantly, a marked increase was noted in the intracellular depots of glycogen (70%). It is suggested that the hormone's antiglycolytic effect in cartilage caused the glucose metabolic pathway to divert in the direction of glycogen synthesis, and thereby interfered with the normal synthetic pathway of the chondrocytes. The hormone's primary effect on the cells' hexose metabolism could be responsible, at least in part, for its inhibitory influence on bone growth.

The quantification of formazans in tissue sections by microdensitometry. I. The use of neotetrazolium chloride

This article describes the use of a microdensitometer for the measurement of formazan deposits in tissue sections. Some examples are given to illustrate the various applications of this technique in the assessment of glucose-6-phosphate dehydrogenase activity. These are (I) the separate measurement of the red half-formazan intermediate and purple diformazan of neotetrazolium, and the effect of incubation time on their production, (2) the measurement of activities in different regions of the liver lobule, and the selective effect of phenobarbitone, and (3) the measurement of enzyme activity in individual cartilage cells in normal and osteoarthrosis-prone animals. All activities can be expressed in absolute units as nmol hydrogen/mm3/hr, and thus compared with standard biochemical data. The activities obtained all fall within the range of published values for biochemical systems.

Tetrazolium salts and formazans

The history of the tetrazolium salts and formazans goes back 100 years, to when Friese (1875) reacted benzene diazonium nitrate with nitromethane, to produce a cherry-red "Neue Verbindung". This was the first formazan. 19 years later, Von Pechmann and Runge (1894) oxidised a formazan to produce the first tetrazolium salt. Many hundreds of tetrazolium salts and formazans were prepared in the following years, but only a handful have found applications in biological research. This article has attempted to describe the properties of these compounds, and to illustrate how the tetrazolium salt-formazan reaction has been exploited to serve an extremely wide variety of functions.